Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer

Rosenthal, Seth I; Depowski, Peter L.; Sheehan, Christine E.; Ross, Jeffrey S.

doi:10.1097/00129039-200203000-00007

Cited by 45 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C35 can be an important novel biomarker for ILC, especially due to lack of expression of other biomarkers, such as HER-2/neu, in this type of breast cancer. Lobular carcinoma has been shown in other studies to be ERBB2 negative (20), in agreement with the data presented. Another significant finding is the correlation of C35 positivity with younger ILC patients (Fig.…”

Section: Regulation Of C35 Transcriptionsupporting

confidence: 92%

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

Evans

Henn²,

Jonason

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Regulation Of C35 Transcriptionsupporting

confidence: 92%

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

Evans

Henn²,

Jonason

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…[46][47][48] 8p deletions were unevenly distributed between breast cancer subtypes, providing further support for the existence of biological differences between different subtypes of breast cancer. The higher rate of 8p deletions in NST as compared to lobular cancer is not surprising as most genomic alterations are more frequent in NST than in lobular carcinomas such as amplifications of HER2, 41,49 MYC, 41 MDM1, 41 and AIB1, 50 or overexpression of p53. 51 A higher rate of 8p deletions in NST than in lobular carcinomas has earlier been suggested by data from Guenther et al 52 finding loss of 8p in 28% of NST but only in 5% of lobular carcinomas (p D 0.05) and by Thor et al 53 reporting 8p in 33% of NST but only in 13% of lobular carcinomas (p D 0.12).…”

Section: Discussionmentioning

confidence: 99%

8p deletion is strongly linked to poor prognosis in breast cancer

Lebok

Mittenzwei

Kluth

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Deletions of chromosome 8p occur frequently in breast cancers, but analyses of its clinical relevance have been limited to small patient cohorts and provided controversial results. A tissue microarray with 2,197 breast cancers was thus analyzed by fluorescence in-situ hybridization using an 8p21 probe in combination with a centromere 8 reference probe. 8p deletions were found in 50% of carcinomas with no special type, 67% of papillary, 28% of tubular, 37% of lobular cancers and 56% of cancers with medullary features. Deletions were always heterozygous. 8p deletion was significantly linked to advanced tumor stage (P < 0.0001), high-grade (P < 0.0001), high tumor cell proliferation (Ki67 Labeling Index; P < 0.0001), and shortened overall survival (P < 0.0001). For example, 8p deletion was seen in 32% of 290 grade 1, 43% of 438 grade 2, and 65% of 427 grade 3 cancers. In addition, 8p deletions were strongly linked to amplification of MYC (P < 0.0001), HER2 (P < 0.0001), and CCND1 (p D 0.001), but inversely associated with ER receptor expression (p D 0.0001). Remarkably, 46.5% of 8p-deleted cancers harbored amplification of at least one of the analyzed genes as compared to 27.5% amplifications in 8p-non-deleted cancers (P < 0.0001). In conclusion, 8p deletion characterizes a subset of particularly aggressive breast cancers. As 8p deletions are easy to analyze, this feature appears to be highly suited for future DNA based prognostic breast cancer panels. The strong link of 8p deletion with various gene amplifications raises the possibility of a role for regulating genomic stability.

show abstract

“…As also frequently observed in the low-grade ductal type: (1) the great majority of in situ and invasive lobular tumors express significant levels of ER, PR, BCL2, TFF1 and TFF3; (2) they are rarely ERBB2-and P53-positive, and their vimentin, VEGF and EGFR levels are low or null (Domagala et al 1990, Poulsom et al 1997, Lee et al 1998, Frolik et al 2001, Rosenthal et al 2002, Arpino et al 2004. The most noticeable feature distinguishing lobular and (low-grade) ductal tumors is the absence of E-cadherin expression in the former (Berx et al 1996, Vos et al 1997, Lehr et al 2000, Goldstein et al 2001, Wahed et al 2002.…”

Section: Lobular Breast Cancermentioning

confidence: 93%

Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics

Lacroix¹,

Toillon²,

Leclercq³

2004

Endocr Relat Cancer

121

View full text Add to dashboard Cite

It is widely believed that ductal breast cancer dissemination involves a succession of clinical and pathological stages starting with carcinoma in situ, progressing into invasive lesion and culminating in metastatic disease. Such changes have frequently been attributed to the sequential acquisition of various alterations in a single cell followed by clonal selection and expansion, thus leading to intratumor diversity. According to this multi-step view, extensive genotype and phenotype (marker expression, grade) shift may occur in the same tumor during progression; this may lead to the coexistence of molecularly and/or pathologically different areas within the same lesion. An increasing amount of data of various natures now appear to challenge this concept: only a few distinct 'portraits', in relation to estrogen receptor (ER) status and grade, may be found among tumors. Moreover, although undergoing increasing genetic alteration, most individual lesions largely maintain their phenotype when they evolve from in situ to the metastatic state. While many of the data presented here are related to ductal tumors, lobular cancer is also discussed.

show abstract

Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer

Cited by 45 publications

References 29 publications

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

8p deletion is strongly linked to poor prognosis in breast cancer

Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics

Contact Info

Product

Resources

About